Jazz Pharmaceuticals plc

As of June 30, 2026, Jazz Pharmaceuticals PLC Unsponsored BDR carries a market capitalization of 79.97B, placing it among publicly traded companies globally. Its enterprise value stands at 91.39B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Jazz Pharmaceuticals PLC Unsponsored BDR's next confirmed earnings release is scheduled for November 2, 2026.

As of June 30, 2026, Jazz Pharmaceuticals PLC Unsponsored BDR has 961.12M shares outstanding.

As of June 30, 2026, Jazz Pharmaceuticals PLC Unsponsored BDR trades at a trailing price-to-earnings ratio of 15.66. The price-to-sales ratio is 3.20, and the price-to-book ratio stands at 3.22.

As of June 30, 2026, Jazz Pharmaceuticals PLC Unsponsored BDR trades at an EV/EBITDA multiple of 10.95 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.84 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.71 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 91.39B versus a market cap of 79.97B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Jazz Pharmaceuticals PLC Unsponsored BDR maintains a current ratio of 1.78, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 91.83, indicating elevated leverage, while an interest coverage ratio of 9.44 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Jazz Pharmaceuticals PLC Unsponsored BDR posted a return on equity (ROE) of 22.11, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 8.54, measuring how efficiently the asset base is converted into earnings. The company generates approximately 8.29M in revenue per employee across its workforce of 2,867.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.12 indicates how many times Jazz Pharmaceuticals PLC Unsponsored BDR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Jazz Pharmaceuticals PLC Unsponsored BDR recorded an income tax benefit of -1.10B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 3.76B, leaving 4.86B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Jazz Pharmaceuticals PLC Unsponsored BDR's stock has gained approximately 79.20% over the past 52 weeks. The 50-day moving average sits at 82.91, while the 200-day moving average is 66.00.

Over the twelve months ended June 30, 2026, Jazz Pharmaceuticals PLC Unsponsored BDR generated 23.78B in revenue and converted that into 4.86B in net income, yielding earnings per share of 5.03. EBITDA reached 8.35B, while operating income came in at 5.25B.

As of June 30, 2026, Jazz Pharmaceuticals PLC Unsponsored BDR holds 11.37B in cash and equivalents against 22.79B in total debt, resulting in a net debt position of 14.12B. Total book value stands at 24.82B, with working capital of 8.98B providing operational flexibility.

Jazz Pharmaceuticals PLC Unsponsored BDR produced 8.59B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.81B in capital expenditures, free cash flow totaled 6.78B - equivalent to 7.40 per share.

Over the twelve months ended June 30, 2026, Jazz Pharmaceuticals PLC Unsponsored BDR posted a gross margin of 88.42, reflecting its pricing power and cost economics. The operating margin of 22.09 and net profit margin of 20.45 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 8.43, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.52, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Jazz Pharmaceuticals PLC Unsponsored BDR shareholders.

As of June 30, 2026, Jazz Pharmaceuticals PLC Unsponsored BDR has an Altman Z-Score of 3.69, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.